Literature DB >> 25724366

Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.

Naoto Fujiwara1, Hayato Nakagawa1, Yotaro Kudo1, Ryosuke Tateishi2, Masataka Taguri3, Takeyuki Watadani4, Ryo Nakagomi1, Mayuko Kondo1, Takuma Nakatsuka1, Tatsuya Minami1, Masaya Sato1, Koji Uchino1, Kenichiro Enooku1, Yuji Kondo1, Yoshinari Asaoka1, Yasuo Tanaka1, Kuni Ohtomo4, Shuichiro Shiina5, Kazuhiko Koike1.   

Abstract

BACKGROUND & AIMS: Obesity defined by body mass index (BMI) significantly increases the risk of hepatocellular carcinoma (HCC). In contrast, not only obesity but also underweight is associated with poor prognosis in patients with HCC. Differences in body composition rather than BMI were suggested to be true determinants of prognosis. However, this hypothesis has not been demonstrated conclusively.
METHODS: We measured skeletal muscle index (SMI), mean muscle attenuation (MA), visceral adipose tissue index, subcutaneous adipose tissue index, and visceral to subcutaneous adipose tissue area ratios (VSR) via computed tomography in a large-scale retrospective cohort of 1257 patients with different stages of HCC, and comprehensively analyzed the impact of body composition on the prognoses.
RESULTS: Among five body composition components, low SMI (called sarcopenia), low MA (called intramuscular fat [IMF] deposition), and high VSR (called visceral adiposity) were significantly associated with mortality, independently of cancer stage or Child-Pugh class. A multivariate analysis revealed that sarcopenia (hazard ratio [HR], 1.52; 95% confidence interval [CI], 1.18-1.96; p=0.001), IMF deposition (HR, 1.34; 95% CI, 1.05-1.71; p=0.020), and visceral adiposity (HR, 1.35; 95% CI, 1.09-1.66; p=0.005) but not BMI were significant predictors of survival. The prevalence of poor prognostic body composition components was significantly higher in underweight and obese patients than in normal weight patients.
CONCLUSIONS: Sarcopenia, IMF deposition, and visceral adiposity independently predict mortality in patients with HCC. Body composition rather than BMI is a major determinant of prognosis in patients with HCC.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Body composition; Body mass index; Hepatocellular carcinoma; Prognosis

Mesh:

Year:  2015        PMID: 25724366     DOI: 10.1016/j.jhep.2015.02.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  173 in total

Review 1.  The Plausibility of Obesity Paradox in Cancer-Point.

Authors:  Yikyung Park; Lindsay L Peterson; Graham A Colditz
Journal:  Cancer Res       Date:  2018-04-15       Impact factor: 12.701

Review 2.  The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint.

Authors:  Bette J Caan; Elizabeth M Cespedes Feliciano; Candyce H Kroenke
Journal:  Cancer Res       Date:  2018-04-15       Impact factor: 12.701

3.  Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.

Authors:  Takashi Shida; Kentaro Akiyama; Sechang Oh; Akemi Sawai; Tomonori Isobe; Yoshikazu Okamoto; Kazunori Ishige; Yuji Mizokami; Kenji Yamagata; Kojiro Onizawa; Hironori Tanaka; Hiroko Iijima; Junichi Shoda
Journal:  J Gastroenterol       Date:  2017-08-08       Impact factor: 7.527

4.  Postoperative Skeletal Muscle Loss Predicts Poor Prognosis of Adenocarcinoma of Upper Stomach and Esophagogastric Junction.

Authors:  Kensuke Kudou; Hiroshi Saeki; Yuichiro Nakashima; Koichi Kimura; Koji Ando; Eiji Oki; Tetsuo Ikeda; Yoshihiko Maehara
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

5.  Low radiographic muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients.

Authors:  Harm van Baar; S Beijer; M J L Bours; M P Weijenberg; M van Zutphen; F J B van Duijnhoven; G D Slooter; J F M Pruijt; J J Dronkers; A Haringhuizen; E J Spillenaar Bilgen; B M E Hansson; J H W de Wilt; E Kampman; R M Winkels
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-17       Impact factor: 4.553

6.  Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

Review 7.  Dysregulated fatty acid metabolism in hepatocellular carcinoma.

Authors:  Mingda Wang; Jun Han; Hao Xing; Han Zhang; Zhenli Li; Lei Liang; Chao Li; Shuyang Dai; Mengchao Wu; Feng Shen; Tian Yang
Journal:  Hepat Oncol       Date:  2017-06-30

8.  Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.

Authors:  George N Ioannou; Pamela Green; Elliott Lowy; Elijah J Mun; Kristin Berry
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

Review 9.  The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.

Authors:  Hánah N Rier; Agnes Jager; Stefan Sleijfer; Andrea B Maier; Mark-David Levin
Journal:  Oncologist       Date:  2016-07-13

10.  Body fat indices and survival in immunotherapy-treated patients with cancer.

Authors:  Rachael M Orlandella; Jennifer R Bail; Michael Behring; Karina I Halilova; Roman Johnson; Victoria Williams; Lyse A Norian; Wendy Demark-Wahnefried
Journal:  Cancer       Date:  2020-04-14       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.